Clinical Trial Update: Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing safety and tolerability of repeat dosing of GSK233705/GW642444 in chronic obstructive pulmonary disease has completed with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GSK233705/GW642444

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED | Results posted: 2020-09-01